RaySearch Laboratories AB Class B ( (RSLBF) ) has released its Q2 earnings. Here is a breakdown of the information RaySearch Laboratories AB Class B presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RaySearch Laboratories AB is a medical technology company specializing in software solutions to enhance cancer treatment, operating within the healthcare industry. In the second quarter of 2025, RaySearch Laboratories reported a decline in net sales by 4.4% compared to the previous year, with a notable decrease in license revenue and an increase in support revenue. The company also launched new versions of its RayStation and RayCare systems, highlighting advancements in treatment planning and clinical workflow management. Despite the decline in quarterly sales, the company experienced a strong order intake for the first half of 2025, indicating robust demand for its products. Looking ahead, RaySearch remains optimistic about its growth prospects, maintaining its operating margin target and focusing on strategic partnerships to drive future success.